Allergic rhinitis Yaprabchombhutaweeb,
Conditions
Interventions
Yaprabchombhutaweeb 450 mg/capsule (Mixed herbal formulation),Loratadine 10 mg/tablet
Experimental Drug,Active Comparator Drug
Yaprabchombhutaweeb,Loratadine
Sponsors
Agricultural Research Development Agency (Public Organization)
None,None
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Male or female with age 18-60 years 2. Patients that diagnosed allergic rhinitis or 3. Patients who had a history of allergic cause and one or more of the following symptoms: nasal congestion, runny nose, itchy nose, or sneezing and 4. Patients who presented watery rhinorrhea or runny nose with one or more of the following symptoms: nasal congestion, itchy nose, sneezing, itchy watery eye
Exclusion criteria
Exclusion criteria: 1. Patients with complication of allergic rhinitis such as rhinosinusitis or upper respiratory tract infection, fever (body temperature > 38.5 oC ) 2. Patients with abnormal nasal structure and needed current medication such as Nasal Polyp 3. Patients with allergic rhinitis requiring topical or oral medications containing anti-histamine drug within 7 days before starting date of study 4. Patients who requiring medications that interfere with Yaprabchomphutaweeb or loratadine such as phenytoin, propranolol, rifampicin 5. Patients with other conditions that would interfere with the assessments such as uncontrolled COPD 6. Patients who present symptom of peptic ulcer or GERD 7. Pregnant women 8. Nursing or breast feeding women 9. Patients with renal impairment or abnormal of liver enzyme 10. The drinker or smoker
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Success rate (no symptoms or TNSS-4 score improve > 80%), improvement rate (TNSS-4 score improve >50 At week 4 Total nasal symptom scores -4 scale (TNSS-4) questionnaire assessed by physician | — |
Secondary
| Measure | Time frame |
|---|---|
| The difference of Total nasal symptom scores 4 scale, quality of life score, ADRs, AEs, time to cure At week 1, 2, 4 TNSS-4, Rcq-36 questionnaire (QOL of chronic allergic rhinitis patient), ADR, AEs | — |
Countries
Thailand
Contacts
Public ContactRatree Sawangjit
Faculty of Pharmacy, Mahasarakham University
Outcome results
None listed